Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone–Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease

Figure 2.
Figure 2. Kaplan–Meier estimates of the probability of remaining free of exacerbations, according to treatment assignment.

The unadjusted hazard ratio was 1.02 (95% CI, 0.77 to 1.37) for tiotropium plus placebo versus tiotropium plus salmeterol (P = 0.87) and 0.80 (CI, 0.60 to 1.08) for tiotropium plus placebo versus tiotropium plus fluticasone–salmeterol (P = 0.15). COPD = chronic obstructive pulmonary disease.

This Article

  1. Published Ahead of Print February 19, 2007, Ann Intern Med April 17, 2007 vol. 146 no. 8 545-555
  1. AbstractFREE
  2. Figures
  3. Full Text
  4. Full Text (PDF)
  5. Related Information

Current Issue

  1. December 15, 2009, 151 (12)
  1. Alert me to current issues